Soluble CTLA-4 and high-risk genetic variants: A new frontier in pancreatic ductal adenocarcinoma (PDAC) biomarkers
These findings highlight the potential of CTLA-4 SNPs and sCTLA-4 as biomarkers for PDAC diagnosis and prognosis. Integrating these biomarkers into screening programs can offer improved strategies for early detection and disease management in high-risk populations.
Authors
- Yasmine Elhusseny (ORCID: https://orcid.org/0000-0002-2796-9423)
- Mahmoud Balata (ORCID: https://orcid.org/0000-0003-4744-1703)
- Magda Azmy (ORCID: https://orcid.org/0000-0002-1309-4099)
- Marwa Hassan (ORCID: https://orcid.org/0000-0001-9751-8129)
- Fatma Elbatol Agamy
Institutions
- Cairo University (EG)
- Misr University for Science and Technology (EG)
- Al-Azhar University (EG)
- University Hospital Bonn (DE)
- University of Rostock (DE)
- Theodor Bilharz Research Institute (EG)
Publication Details
- Journal
- Biochemistry and Biophysics Reports
- Published
- 2025-10-15
- DOI
- https://doi.org/10.1016/j.bbrep.2025.102304
- Citations
- 1
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 1.05